opentargets/clinical_trial_reason_to_stop · Datasets at Hugging Face

text stringlengths 4 164	label_descriptions sequence	Another_Study bool 2 classes	Business_Administrative bool 2 classes	Covid19 bool 2 classes	Endpoint_Met bool 2 classes	Ethical_Reason bool 2 classes	Insufficient_Data bool 2 classes	Insufficient_Enrollment bool 2 classes	Interim_Analysis bool 2 classes	Invalid_Reason bool 2 classes	Logistics_Resources bool 2 classes	Negative bool 2 classes	No_Context bool 2 classes	Regulatory bool 2 classes	Safety_Sideeffects bool 2 classes	Study_Design bool 2 classes	Study_Staff_Moved bool 2 classes	Success bool 2 classes
Due to recent strategic policy developments in the national vaccination program it is uncertain preadolescent girls will receive the HBV vaccin.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Due to regulatory/compliance observations noted in a Data Safety Monitoring Board UCSD audit report & requirements by NIH/Recombinant DNA Advisory Committee.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Due to reported toxicity of Celecoxib at high doses	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to results of conditional power analysis performed at the first interim analysis and due to observed spectrum of adverse events.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to safety concerns	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33AÊ arm versus the control arm	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to slow accrual	[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]	false	true	false	false	false	false	true	false	false	true	false	false	false	false	false	false	false
Due to slow accrual of patients	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to slow participant accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to slow recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to slow recruitment and a delay in reaching the recruitment target.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to slow recruitment and a significant delay in reaching the recruitment target.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to slow, insufficient accrual.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to specimen collection difficulties; this study has been terminated	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to strategic reasons	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to strict inclusion and exclusion criteria no subjects were enrolled	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to strict measures of the government to contain the spread of COVID-19 outbreak, we follow	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to supply constraints & prioritization according to medical need (availability ofÊ alternative rabies vaccines), Rabipur will no longer be supplied to China.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to technical issues relating to the Electronic diary data.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Due to termination of study D3801C00001, due to reports of turbid urine."	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the COVID-19 pandemic, recruitment and screening visits have been suspended until	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the COVID-19 pandemic, recruitment and screening visits have been suspended untilÊ further notice.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the COVID-19 pandemic, study has been temporarily halted and will resume in the future	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the COVID-19 pandemic, this study has temporarily suspended recruitment activities.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the COVID-19 pandemic, this study has temporarily suspended recruitment activities.Ê Other elements of the study are ongoing.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the achievement of minimum required sample size and new changes in local regulations.	[ "Business_Administrative", "Invalid_Reason" ]	false	true	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study Ê had to be terminated.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to the current COVID-19 pandemic, the recruitment of new subjects is temporarily	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the current COVID-19 pandemic, the recruitment of new subjects is temporarilyÊ discontinued. Ongoing, randomised patients are managed per Trial Protocol.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the high rate of morbidity and mortality	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to the impact of COVID-19	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the lack of enrolment and complexity of design, the QAX576A2103 study in asthma was terminated. No subjects have been dosed for this study."	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Due to the meta-analysis about CV adverse effects of rosiglitazone.	[ "Safety_Sideeffects", "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	true	false	false	false
Due to the publication of significant literature in this area since commencement of the project which has now rendered the project unnecessary.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the recent meta-analysis about CV adverse effects.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the results of interim analysis at the time 44 patients were recruited.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to the sale of Cardene IV, the sponsor has stopped enrollment and terminated the study. No safety issues were identified."	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Due to the slow rate of recruitment the study was stopped.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology indications.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology Ê indications.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Due to toxicity of cyclophosphamide	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Due to unforeseen circumstances this study will not now start.	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Due to unforseen recruiting difficulties, the study was closed.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to unmet accrual/randomization goals	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Due to unstalbe cell sheet quality. We didn't use this tech on patients.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
During routine safety review of Studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated"	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
During the study	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of brainstem toxicity/encephalopathy during lidocaine/saline infusion"	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
ECOG will not proceed with activation	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in the atacicept treatment groups compared to placebo	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS [Please refer to ATAMS]	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
EORTC trail showed TMZ & RT conferred significant survivial in this population	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Early Phase I study of [123I]MNI-340 did not evidence as marker of disease	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Early stopping rule	[ "Ethical_Reason", "Negative" ]	false	false	false	false	true	false	false	false	false	false	true	false	false	false	false	false	false
Early termination due to efficacy	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Early termination due to loss of interest and low enrollment of patient	[ "Business_Administrative", "Insufficient_Enrollment" ]	false	true	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Early termination of IDX21459 was due to integration of Merck's HCV antiviral pipeline hasÊ resulted in revisions of the clinical development plan.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferativeÊ disorder	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Effects of aripiprazole was not obvious and showed adverse reaction obviously	[ "Safety_Sideeffects", "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	true	false	false	false
Efficacy	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Efficacy in pre-trial subjects indicated that the intervention did not warrant further investigation	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Efficacy not evident in this population.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Efficacy rates did not show large enough differences between treatments	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Efficacy seen in the solid tumour patient population was not sufficient to continue research with AZD1152 monotherapy in solid tumors at that time.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Efficacy was not cleared at US study	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Efforts at recruitment have halted as recruitment was poor.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Elevation of ALT and AST in some patients.	[ "Safety_Sideeffects", "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	true	false	false	false
End of Agreement between BMS and SGHL	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
End of recruitment period	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
End of research time, time-resources"	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
End of study time and budget permission	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
End of the recruitment	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
End of the study	[ "Endpoint_Met", "Invalid_Reason" ]	false	false	false	true	false	false	false	false	true	false	false	false	false	false	false	false	false
Ended prematurely - The trial never commenced.	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Endpoint no longer deemed meaningful	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Enrolled requested number of patients and completed study. In analysis	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Enrolled subjects were unable to receive drug from dispensing pharmacy.	[ "Logistics_Resources", "Study_Design" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	true	false	false
Enrollement target could not be achieved, study will potentially be resumed"	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment Suspended	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Enrollment and interactions/interventions paused due to COVID-19. Expected to resume in the	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment and interactions/interventions temporarily paused due to COVID-19 & will resume in	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment and interventions are temporarily paused due to COVID-19 and are expected to resume	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment and study activities are temporarily suspended due to COVID-19.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment below goal.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment by invitation only	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Enrollment challenges prohibited study progression.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment closed	[ "Insufficient_Enrollment", "Invalid_Reason" ]	false	false	false	false	false	false	true	false	true	false	false	false	false	false	false	false	false
Enrollment completed	[ "Endpoint_Met", "Invalid_Reason" ]	false	false	false	true	false	false	false	false	true	false	false	false	false	false	false	false	false
Enrollment criteria met	[ "Endpoint_Met", "Invalid_Reason" ]	false	false	false	true	false	false	false	false	true	false	false	false	false	false	false	false	false
Enrollment difficulties	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment discontinued after second cohort completed.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Enrollment discontinued pending protocol modification considerations.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Enrollment failed	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false

Due to recent strategic policy developments in the national vaccination program it is uncertain preadolescent girls will receive the HBV vaccin.

[ "Regulatory" ]

false

true

false

Due to regulatory/compliance observations noted in a Data Safety Monitoring Board UCSD audit report & requirements by NIH/Recombinant DNA Advisory Committee.

[ "Regulatory" ]

false

true

false

Due to reported toxicity of Celecoxib at high doses

[ "Safety_Sideeffects" ]

false

true

false

Due to results of conditional power analysis performed at the first interim analysis and due to observed spectrum of adverse events.

[ "Negative" ]

false

true

false

Due to safety concerns

[ "Safety_Sideeffects" ]

false

true

false

Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33AÊ arm versus the control arm

[ "Safety_Sideeffects" ]

false

true

false

Due to slow accrual

[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]

false

true

false

true

false

true

false

Due to slow accrual of patients

[ "Insufficient_Enrollment" ]

false

true

false

Due to slow participant accrual

[ "Insufficient_Enrollment" ]

false

true

false

Due to slow recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Due to slow recruitment and a delay in reaching the recruitment target.

[ "Insufficient_Enrollment" ]

false

true

false

Due to slow recruitment and a significant delay in reaching the recruitment target.

[ "Insufficient_Enrollment" ]

false

true

false

Due to slow, insufficient accrual.

[ "Insufficient_Enrollment" ]

false

true

false

Due to specimen collection difficulties; this study has been terminated

[ "Insufficient_Enrollment" ]

false

true

false

Due to strategic reasons

[ "Business_Administrative" ]

false

true

false

Due to strict inclusion and exclusion criteria no subjects were enrolled

[ "Insufficient_Enrollment" ]

false

true

false

Due to strict measures of the government to contain the spread of COVID-19 outbreak, we follow

[ "Covid19" ]

false

true

false

Due to supply constraints & prioritization according to medical need (availability ofÊ alternative rabies vaccines), Rabipur will no longer be supplied to China.

[ "Logistics_Resources" ]

false

true

false

Due to technical issues relating to the Electronic diary data.

[ "Logistics_Resources" ]

false

true

false

Due to termination of study D3801C00001, due to reports of turbid urine."

[ "Another_Study" ]

true

false

Due to the COVID-19 pandemic, recruitment and screening visits have been suspended until

[ "Covid19" ]

false

true

false

Due to the COVID-19 pandemic, recruitment and screening visits have been suspended untilÊ further notice.

[ "Covid19" ]

false

true

false

Due to the COVID-19 pandemic, study has been temporarily halted and will resume in the future

[ "Covid19" ]

false

true

false

Due to the COVID-19 pandemic, this study has temporarily suspended recruitment activities.

[ "Covid19" ]

false

true

false

Due to the COVID-19 pandemic, this study has temporarily suspended recruitment activities.Ê Other elements of the study are ongoing.

[ "Covid19" ]

false

true

false

Due to the achievement of minimum required sample size and new changes in local regulations.

[ "Business_Administrative", "Invalid_Reason" ]

false

true

false

true

false

Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study Ê had to be terminated.

[ "Study_Design" ]

false

true

false

Due to the current COVID-19 pandemic, the recruitment of new subjects is temporarily

[ "Covid19" ]

false

true

false

Due to the current COVID-19 pandemic, the recruitment of new subjects is temporarilyÊ discontinued. Ongoing, randomised patients are managed per Trial Protocol.

[ "Covid19" ]

false

true

false

Due to the high rate of morbidity and mortality

[ "Negative" ]

false

true

false

Due to the impact of COVID-19

[ "Covid19" ]

false

true

false

Due to the lack of enrolment and complexity of design, the QAX576A2103 study in asthma was terminated. No subjects have been dosed for this study."

[ "Study_Design" ]

false

true

false

Due to the meta-analysis about CV adverse effects of rosiglitazone.

[ "Safety_Sideeffects", "Negative" ]

false

true

false

true

false

Due to the publication of significant literature in this area since commencement of the project which has now rendered the project unnecessary.

[ "Another_Study" ]

true

false

Due to the recent meta-analysis about CV adverse effects.

[ "Another_Study" ]

true

false

Due to the results of interim analysis at the time 44 patients were recruited.

[ "Negative" ]

false

true

false

Due to the sale of Cardene IV, the sponsor has stopped enrollment and terminated the study. No safety issues were identified."

[ "Business_Administrative" ]

false

true

false

Due to the slow rate of recruitment the study was stopped.

[ "Insufficient_Enrollment" ]

false

true

false

Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology indications.

[ "Regulatory" ]

false

true

false

Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology Ê indications.

[ "Regulatory" ]

false

true

false

Due to toxicity of cyclophosphamide

[ "Safety_Sideeffects" ]

false

true

false

Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses."

[ "Negative" ]

false

true

false

Due to unforeseen circumstances this study will not now start.

[ "Invalid_Reason" ]

false

true

false

Due to unforseen recruiting difficulties, the study was closed.

[ "Insufficient_Enrollment" ]

false

true

false

Due to unmet accrual/randomization goals

[ "Insufficient_Enrollment" ]

false

true

false

Due to unstalbe cell sheet quality. We didn't use this tech on patients.

[ "Logistics_Resources" ]

false

true

false

During routine safety review of Studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated"

[ "Another_Study" ]

true

false

During the study

[ "Invalid_Reason" ]

false

true

false

During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of brainstem toxicity/encephalopathy during lidocaine/saline infusion"

[ "Safety_Sideeffects" ]

false

true

false

ECOG will not proceed with activation

[ "Negative" ]

false

true

false

EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in the atacicept treatment groups compared to placebo

[ "Safety_Sideeffects" ]

false

true

false

EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS [Please refer to ATAMS]

[ "Another_Study" ]

true

false

EORTC trail showed TMZ & RT conferred significant survivial in this population

[ "Another_Study" ]

true

false

Early Phase I study of [123I]MNI-340 did not evidence as marker of disease

[ "Another_Study" ]

true

false

Early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints

[ "Study_Design" ]

false

true

false

Early stopping rule

[ "Ethical_Reason", "Negative" ]

false

true

false

true

false

Early termination due to efficacy

[ "Negative" ]

false

true

false

Early termination due to loss of interest and low enrollment of patient

[ "Business_Administrative", "Insufficient_Enrollment" ]

false

true

false

true

false

Early termination of IDX21459 was due to integration of Merck's HCV antiviral pipeline hasÊ resulted in revisions of the clinical development plan.

[ "Business_Administrative" ]

false

true

false

Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferativeÊ disorder

[ "Safety_Sideeffects" ]

false

true

false

Effects of aripiprazole was not obvious and showed adverse reaction obviously

[ "Safety_Sideeffects", "Negative" ]

false

true

false

true

false

Efficacy

[ "Negative" ]

false

true

false

Efficacy in pre-trial subjects indicated that the intervention did not warrant further investigation

[ "Another_Study" ]

true

false

Efficacy not evident in this population.

[ "Negative" ]

false

true

false

Efficacy rates did not show large enough differences between treatments

[ "Negative" ]

false

true

false

Efficacy seen in the solid tumour patient population was not sufficient to continue research with AZD1152 monotherapy in solid tumors at that time.

[ "Negative" ]

false

true

false

Efficacy was not cleared at US study

[ "Negative" ]

false

true

false

Efforts at recruitment have halted as recruitment was poor.

[ "Insufficient_Enrollment" ]

false

true

false

Elevation of ALT and AST in some patients.

[ "Safety_Sideeffects", "Negative" ]

false

true

false

true

false

End of Agreement between BMS and SGHL

[ "Business_Administrative" ]

false

true

false

End of recruitment period

[ "Invalid_Reason" ]

false

true

false

End of research time, time-resources"

[ "Logistics_Resources" ]

false

true

false

End of study time and budget permission

[ "Business_Administrative" ]

false

true

false

End of the recruitment

[ "Invalid_Reason" ]

false

true

false

End of the study

[ "Endpoint_Met", "Invalid_Reason" ]

false

true

false

true

false

Ended prematurely - The trial never commenced.

[ "Invalid_Reason" ]

false

true

false

Endpoint no longer deemed meaningful

[ "Study_Design" ]

false

true

false

Enrolled requested number of patients and completed study. In analysis

[ "Invalid_Reason" ]

false

true

false

Enrolled subjects were unable to receive drug from dispensing pharmacy.

[ "Logistics_Resources", "Study_Design" ]

false

true

false

true

false

Enrollement target could not be achieved, study will potentially be resumed"

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment Suspended

[ "Invalid_Reason" ]

false

true

false

Enrollment and interactions/interventions paused due to COVID-19. Expected to resume in the

[ "Covid19" ]

false

true

false

Enrollment and interactions/interventions temporarily paused due to COVID-19 & will resume in

[ "Covid19" ]

false

true

false

Enrollment and interventions are temporarily paused due to COVID-19 and are expected to resume

[ "Covid19" ]

false

true

false

Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected

[ "Covid19" ]

false

true

false

Enrollment and study activities are temporarily suspended due to COVID-19.

[ "Covid19" ]

false

true

false

Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to

[ "Covid19" ]

false

true

false

Enrollment below goal.

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment by invitation only

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.

[ "Study_Design" ]

false

true

false

Enrollment challenges prohibited study progression.

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment closed

[ "Insufficient_Enrollment", "Invalid_Reason" ]

false

true

false

true

false

Enrollment completed

[ "Endpoint_Met", "Invalid_Reason" ]

false

true

false

true

false

Enrollment criteria met

[ "Endpoint_Met", "Invalid_Reason" ]

false

true

false

true

false

Enrollment difficulties

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment discontinued after second cohort completed.

[ "Insufficient_Enrollment" ]

false

true

false

Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor

[ "Business_Administrative" ]

false

true

false

Enrollment discontinued pending protocol modification considerations.

[ "Study_Design" ]

false

true

false

Enrollment failed

[ "Insufficient_Enrollment" ]

false

true

false